Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 2c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.60), $0.02 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• Six Flags names Mark Pauls as chief operating officer